CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 263 enrolled
Drug / intervention
Nepafenac ophthalmic suspension, 0.1% (NEVANAC) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00782717
NCT00782717Phase 2Completed
CompareCT.gov

A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients

Alcon Research·interventional·Posted Oct 31, 2008·Updated Oct 26, 2012

In Brief

A Phase 2 clinical trial evaluating Nepafenac ophthalmic suspension, 0.1% (NEVANAC), Nepafenac ophthalmic suspension vehicle, and 1 other intervention for Macular Edema. Completed, enrolled 263 participants.

Detailed Summary

The purpose of this study is to determine whether nepafenac is safe and effective for reducing the incidence of macular edema following cataract surgery in diabetic retinopathy patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Edema
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 31, 2008
Enrollment StartNov 1, 2008
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 17.7 years ago

Interventions

Nepafenac ophthalmic suspension, 0.1% (NEVANAC)drug

1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery.

Nepafenac ophthalmic suspension vehicleother

1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery

Prednisolone acetate ophthalmic suspension (OMNIPRED)drug

One drop in the study eye 4 times daily (morning, late morning, late afternoon, and bedtime)for two weeks postsurgery.